Answers are grounded in this paper and cite their sources.
Amyloid-targeting therapies provide disease-modifying treatment for early symptomatic Alzheimer’s disease (AD), but the number of individuals potentially eligible for treatment in China remains uncertain. We aimed to synthesize the prevalence of mild cognitive impairment (MCI) and AD among older adults in China and quantify the population potentially eligible for amyloid-targeting therapies. PubMed, Web of Science, SinoMed, and China National Knowledge Infrastructure were searched from January 1, 2020 through August 6, 2026. Population-based observational studies reporting MCI or AD prevalence among adults aged ≥ 60 years in mainland China were included; studies restricted to selected disease subgroups and non-primary reports were excluded. Methodological quality was assessed using the Joanna Briggs Institute Checklist for Prevalence Studies. Prevalence estimates were synthesized using random-effects meta-analysis and incorporated into a stepwise funnel model accounting for healthcare consultation, clinical diagnosis, biomarker testing, and amyloid positivity. Scenario and probabilistic sensitivity analyses assessed uncertainty. Twenty-seven studies involving 312,204 participants were included; most were of moderate quality. Pooled prevalence was 21.21% [95% confidence interval (CI) 17.41–25.01%; I 2 = 99.7%] for MCI and 4.72% (95% CI 3.13–6.31%; I 2 = 99.8%) for AD. Under current healthcare consultation, diagnostic, and biomarker testing conditions, an estimated 39,825 individuals were potentially eligible for amyloid-targeting therapies. When these constraints were removed, the estimated potentially eligible population increased to 14.17 million. Study heterogeneity was substantial, and age-stratified evidence was limited. China has a substantial population potentially eligible for amyloid-targeting therapies, but current healthcare consultation, diagnostic, and biomarker testing constraints markedly limit treatment access. These estimates can inform diagnostic capacity planning, resource allocation, treatment access, and reimbursement decisions.
No takes yet. Share an insight, caveat, or question.
Lian et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: